EML4-ALK variant-specific genetic interactions shape lung tumorigenesis
Alberto Diaz-JimeneziD, Emily G. ShuldineriD, Kálmán SomogyiiD, Karen Y. ShihiD, Óscar González-VelascoiD, Mulham NajajrehiD, Stewart J. KimiD, Filiz AkkasiD, Christopher W. MurrayiD, Laura AndrejkaiD, Min K. TsaiiD, Benedikt BrorsiD, Ilse HofmanniD, Smruthy SivakumariD, Saumya Dushyant SisoudiyaiD, Ethan S. SokoliD, Hongchen CaiiD, Dmitri A. PetroviD, Monte M. WinslowiD, Rocı́o SotilloiD
Abstract
Oncogenic fusions of EML4 and ALK occur in [~]5% of lung adenocarcinomas. More than 15 EML4-ALK variants with distinct breakpoints within EML4 have been identified, but the functional differences between these variants remain poorly understood. Here we use CRISPR/Cas9 somatic genome editing to generate autochthonous mouse models of the two most common EML4-ALK variants, V1 and V3, and show that V3 is more oncogenic than V1. By integrating these models with multiplexed genome editing, we quantify the effects of 29 putative tumor suppressor genes on V1- and V3-driven lung cancer growth in vivo and show that many tumor suppressor genes have dramatically variant-specific effects on tumorigenesis. Analysis of a novel dataset representing the largest human EML4-ALK lung cancer cohort to date identified alterations in the genomic landscape depending on the EML4-ALK variant. These findings demonstrate functional heterogeneity among EML4-ALK variants, suggesting that EML4-ALK variants behave more like distinct oncogenes than a uniform entity. More broadly, these findings highlight the dramatic impact of oncogenic fusions partner proteins on tumor biology.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 8
- FWCI
- 4.75
- Field percentile
- top 4%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- EML4-ALK V3 drives cell migration through NEK9 and NEK7 kinases in non-small-cell lung cancer
L. O'Regan, G. Barone, … A. M. Fry·bioRxiv·Mar 4, 2019
- Phase-separation of EML4-ALK variant 3 is dependent upon an active ALK conformation
J. Sampson, M. Richards, … R. Bayliss·bioRxiv·Jun 11, 2020
- ALK variants Differentially Modulate Neuroblastoma Tumor Behavior and Transcriptome in a Cellular Context-Dependent Manner
El Natour Maya, Lucie Vivancos Stalin, … Annick Mühlethaler‐Mottet·bioRxiv·Sep 10, 2026
- Evolution and clinical impact of genetic epistasis within EGFR-mutant lung cancers
Collin M. Blakely, Thomas B.K. Watkins, … Trever G. Bivona·bioRxiv·Mar 16, 2017
- Loss of Spindly sensitizes EML4-ALK v3 lung cancer cells to HSP90 inhibitors
M. P. Licciardello, C. Zhang, … P. Workman·bioRxiv·Jun 8, 2022
- High-Speed AFM Reveals IDR-Mediated Structural Plasticity of EML4-ALK Modulated by ALK Inhibitors
Xujun Han, Noriyuki Kodera, … Seiji Yano·bioRxiv·Aug 7, 2025